A presentation at the National Community Pharmacists Association Annual Meeting and Exposition focused on the latest on COVID-19 vaccination.
This article originally appeared on Drug Topics®.
A presentation at the National Community Pharmacists Association Annual Meeting and Exposition focused on the latest on COVID-19 vaccination.
Image credit: Konstantin Yuganov - stock.adobe.com
Respiratory virus season is here, according to David Ha, PharmD, BCIDP, but the worst is not upon us yet. The CDC has predicted that this year’s respiratory season is going to look similar—"or maybe slightly less intense”—compared with last year’s season, “but we’ve been fooled before,” Ha said.
In his presentation at this year’s National Community Pharmacists Association (NCPA) Annual Meeting and Exposition, Ha—infectious diseases manager at Stanford Health Care—provided a comprehensive overview of vaccines for 4 common respiratory viruses and touched on the latest updates from the October 2024 CDC Advisory Committee on Immunization Practices (ACIP) meeting, held just days before the conference.
The 2024-2025 COVID-19 vaccine is not a new vaccine, but a strain change. This year’s shots are monovalent, targeting the Omicron JN.1 lineage of SARS-CoV-2. The FDA authorized the new versions of these vaccines—mRNA versions from Moderna and Pfizer, and a protein-based version from Novavax—in August 2024.
Despite the availability of new shots, the low rates of vaccination may be indicative of another phenomenon: COVID-19 fatigue. “You may be getting questions…from your patients. Year after year, new variants, ‘Does it still make sense for me to continue to get vaccinated?’” Ha said. One way to address these questions? Safety and efficacy data from the previous season.
Across all age groups, the 2023-2024 COVID-19 vaccine—a monovalent vaccine targeting the SARS-CoV-2 XBB.1.5 sublineage—was effective against COVID-19 infection, emergency department and urgent care visits, and hospitalizations. What’s more, this efficacy persisted for at least 6 months after immunization, with waning observed around the 4- to-6-month mark. Safety data showed similar rates of adverse reactions to the 2023-2024 vaccine as in prior seasons, and no signal for myocarditis or pericarditis in men aged 12 to 39 years.
“Vaccination rates have declined, as I’m sure you’re aware, in the past [few] years, especially since the peak of the COVID-19 pandemic,” Ha said. Data from earlier this year indicate that more than one-third or less of eligible individuals reported that they are up to date with their COVID-19 vaccination.
But with more than 8 in 10 Americans receiving their COVID-19 vaccinations at a pharmacy, “the responsibility is now in our hands to make sure that we are advocating for COVID-19 vaccination.”
The CDC Advisory Committee on Immunization Practices (ACIP) met on October 23 and 24, 2024, to make recommendations for the 2024-2025 COVID-19 vaccine. At the time of Ha’s presentation (and the writing of this article), those changes had not yet been made to the CDC’s website. Major changes from the ACIP 2024 October update include:
There is no specific timing recommended for COVID-19 vaccination. Protection is at its highest within the first weeks to months after vaccination; therefore, high-risk patients should not wait. Co-administration of the COVID-19 vaccine with other respiratory virus vaccines is encouraged.
For more from this presentation about influenza, respiratory syncytial virus, and pneumococcal disease, check out the full article.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More